Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-341-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.05 billion
Profitability
Miscellaneous
Employees2,500
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable
Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions
What is Vertex Pharmaceuticals' stock symbol?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How will Vertex Pharmaceuticals' stock buyback program work?
Vertex Pharmaceuticals announced that its board has authorized a stock buyback plan on Wednesday, July 31st 2019, which permits the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board believes its shares are undervalued.
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings data on Wednesday, July, 31st. The pharmaceutical company reported $0.99 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.75 by $0.24. The pharmaceutical company earned $941.29 million during the quarter, compared to the consensus estimate of $884.66 million. Vertex Pharmaceuticals had a return on equity of 21.73% and a net margin of 64.13%. The business's revenue was up 25.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.94 EPS. View Vertex Pharmaceuticals' Earnings History.
When is Vertex Pharmaceuticals' next earnings date?
What price target have analysts set for VRTX?
22 analysts have issued 12 month price targets for Vertex Pharmaceuticals' stock. Their predictions range from $165.71 to $254.00. On average, they expect Vertex Pharmaceuticals' share price to reach $214.48 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
What is the consensus analysts' recommendation for Vertex Pharmaceuticals?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.
What are Wall Street analysts saying about Vertex Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Vertex reported 2Q19 with cystic fibrosis (CF) revenue of $940M, beating consensus of $886.2M, up 25% y/y and 10% sequentially. All three approved CF drugs beat consensus; Kalydeco $262M vs. $254.5M, Orkambi $316M vs. $284.2M, and Symdeko $362M vs. $340.8M. Topline flowed through to the bottom line with $1.26 beating consensus of $1.07. Vertex ended the period with $4B in cash." (8/2/2019)
- 2. HC Wainwright analysts commented, "Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.94 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%). Risks to our investment thesis and target price include: (1) the failure of in further combination clinical studies; (2) the failure of to achieve our peak sales revenue; and (3) product competition." (8/1/2019)
- 3. Needham & Company LLC analysts commented, "Vertex reported $857M in 1Q19 WW Cystic Fibrosis sales, above our $842M and consensus $849M ests. Symdeko/ Symkevi is primary growth driver, as expected. Sales and OpEx guidance are unch. Non-GAAP EPS was $1.14, above our $1.04 and consensus $1.01 ests. Full data set from both triple drug CF Phase 3 programs expected in 2Q19 and mgmt reiterated plans to select best regimen for NDA and MAA submissions in 3Q19 and 4Q19, respectively. Vertex moving a new once- daily corrector (VX-121) into triple drug Phase 2 trial w/ VX-561/TEZ in hopes of even greater efficacy. VX-814 announced as first candidate for AAT . A Phase 1 trial is underway w/ more backup cmpds to move into clinic in 2019. NaV1.8 pain strategy update likely in 2H19. BUY. Vertex likely to hold strong competitive position in CF for several yrs." (5/1/2019)
- 4. According to Zacks Investment Research, "A significant increase in the eligible patient population for its CF drugs is driving sales growth at Vertex. Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of growth in CF revenues in 2018. Vertex’s CF pipeline is also accelerating rapidly. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, a switch in patient base to Symdeko from Orkambi is also hurting sales of the latter. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have underperformed the industry this year so far." (3/8/2019)
Has Vertex Pharmaceuticals been receiving favorable news coverage?
News headlines about VRTX stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news headlines about the pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Vertex Pharmaceuticals.
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of Vertex Pharmaceuticals own?
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the folowing people:
- Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
- Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
- Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
- Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)
- Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63)
Who are Vertex Pharmaceuticals' major shareholders?
Vertex Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.36%), Strs Ohio (0.13%), Manning & Napier Group LLC (0.09%), Atalanta Sosnoff Capital LLC (0.08%), Commerzbank Aktiengesellschaft FI (0.08%) and Rhenman & Partners Asset Management AB (0.07%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.
Which major investors are selling Vertex Pharmaceuticals stock?
VRTX stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, TIAA FSB, Candriam Luxembourg S.C.A., Robeco Institutional Asset Management B.V., Gateway Investment Advisers LLC, Atalanta Sosnoff Capital LLC, Nisa Investment Advisors LLC and Enlightenment Research LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals.
Which major investors are buying Vertex Pharmaceuticals stock?
VRTX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Peregrine Capital Management LLC, Oakbrook Investments LLC, State of Alaska Department of Revenue, Broadleaf Partners LLC, Cohen Klingenstein LLC, Pacer Advisors Inc. and Clarus Wealth Advisors. View Insider Buying and Selling for Vertex Pharmaceuticals.
How do I buy shares of Vertex Pharmaceuticals?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals' stock price today?
One share of VRTX stock can currently be purchased for approximately $188.38.
How big of a company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $48.42 billion and generates $3.05 billion in revenue each year. The pharmaceutical company earns $2.10 billion in net income (profit) each year or $2.83 on an earnings per share basis. Vertex Pharmaceuticals employs 2,500 workers across the globe.View Additional Information About Vertex Pharmaceuticals.
What is Vertex Pharmaceuticals' official website?
How can I contact Vertex Pharmaceuticals?
Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]
MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
